-
Heat anti-Parkinson’s Disease——Carbidopa and LevodopaCR Tablets the f...
Recently,China Drug Administration (CDA)publicised the SJZ NO.4 Pharmaceutical approval certificate delivery information, CarbidopaandLevodopaCRTablets approved for listing, deemed t...
See More
-
Technical Guidelines for Clinical Trials of Drugs for Chronic Hepatitis D...
Technical Guidelines for Clinical Trials of Drugs for Chronic Hepatitis D Virus Infection
See More
-
Difference between Ornidazole, Levonidazole, and Levonidazole Phosphate Di...
Ornidazole, Levonidazole, are both approved for the treatment of anaerobic infections and protozoal infections. The structure of Ornidazole contains a chiral carbon atom with a hydroxyl group, whi...
See More
-
Local firms accelerate in oncology track
In recent years, the development of ablation technology in the field of oncology interventional therapy has advanced by leaps and bounds, opening up new possibilities for tumor treatment.According t...
See More
-
Why is there no vaccine for Mycoplasma pneumoniae? How long will it take to d...
However, the urgent clinical needs, seemingly huge market, not only the country, even the world seems to have no "mycoplasma pneumonia" pipeline exposure....
See More
-
New Coronavirus Infection Treatment Atetevir Tablets/Ritonavir Tablets C...
On November 24th, the State Drug Administration conditionally approved the official listing of Atetevir Tablets/Ritonavir Tablets Combination Package (trade name: Taizhongding®), a Class...
See More
-
China Drug Administration (CDA) Releases New Version of "Principles an...
On March 29, the website of China‘s State Drug Administration (SDA) issued a notice on the issuance of principles and procedures for exploratory studies on drug sampling, while the Notice o...
See More
-
Update to living WHO guideline on drugs for covid-19...
The World Health Organization (WHO) has released the ninth update of their living guideline on medications for the treatment of COVID-19 infection (A living WHO guideline on drugs for ...
See More